Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

AIM/MPH stock hub

AIM/MPH has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AIM/MPHis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

29.2M

London Stock Exchange AIM

Market data

Live price

Current market quote for this ticker.

Current price

AIM/MPH

In the news

Latest news · AIM/MPH

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-82.2

P25 n/aP50 n/aP75 n/a

ROIC-44.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AIM/MPH market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

150

Groups with data

Currency

USD

Showing 150 of 150 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	39
Employees Change	3%
Employees Change Percent	8.33
Enterprise value	GBX -697,117
Exchange	London Stock Exchange AIM
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	GBX 29.2M
Price	GBX 26.5
Price currency	GBX
Rev Per Employee	9,525.64x
Sic	2836
Symbol	aim/MPH
Website	https://www.mereobiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-106.42%
EV Earnings	0.02x
EV/FCF	0.03x
FCF yield	-78.76%
P/B ratio	0.96x
P/S ratio	78.7x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	73.4%
Gross Profit	GBX 272,681
Gross Profit Growth3 Y	-31.58%
Net Income	GBX -31.1M
Pretax Margin	-8,375.6%
Profit Per Employee	GBX -797,830
ROA	-39.41
Roa5y	-29.09
ROCE	-92.65
ROE	-82.21
Roe5y	-47.28
ROIC	-44.41

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-5.35%
Cagr3y	-56.85%
EPS Growth Quarters	8

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	GBX 0.01
Assets	GBX 34.1M
Cash	GBX 30.5M
Current Assets	GBX 33M
Current Liabilities	GBX 3.2M
Debt	GBX 150,086
Debt Equity	GBX 0
Debt FCF	GBX -0.01
Equity	GBX 30.4M
Interest Coverage	-151.2
Liabilities	GBX 3.7M
Long Term Assets	GBX 1.1M
Long Term Liabilities	GBX 560,166
Net Cash	GBX 30.3M
Net Cash By Market Cap	GBX 104
Net Cash Growth	-35.64%
Net Debt Equity	GBX -1
Tangible Book Value	GBX 30M
Tangible Book Value Per Share	GBX 0.19

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.46
Net Working Capital	GBX -53,496
Quick ratio	9.99
Working Capital	GBX 30.3M
Working Capital Turnover	GBX 0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-7.77%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-5.36%
200-day SMA	34.79
3Y total return	-91.97%
50-day SMA	33.69
50-day SMA vs 200-day SMA	50under200
All Time High	353
All Time High Change	-92.49%
All Time High Date	2018-04-17
All Time Low	13
All Time Low Change	103.85%
All Time Low Date	2020-03-24
ATR	1.87
Ch YTD	-25.35
High	26.2
High52	60
High52 Date	2020-08-25
High52ch	-55.83%
Low	26
Low52	13
Low52 Date	2020-03-24
Low52ch	103.85%
Ma50ch	-21.34%
Price vs 200-day SMA	-23.83%
RSI	17.95
RSI Monthly	26.52
RSI Weekly	34.39
Sharpe ratio	0.6x
Sortino ratio	1.97
Total Return	-7.77%
Tr YTD	-25.35
Tr1m	-17.19%
Tr1w	-10.17%
Tr3m	-42.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	GBX -28.6M
Operating margin	-7,711.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	114,465,687%
Shares Qo Q	0.06%
Shares Yo Y	7.77%
Short Ratio	4.63

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	GBX -28.7M
Average Volume	133,355.5x
Bv Per Share	0.19
CAPEX	GBX -14,860
Ch1m	-17.19
Ch1w	-10.17
Ch1y	-5.36
Ch3m	-42.39
Ch3y	-91.97
Ch6m	-34.57
Change	-1.85%
Change From Open	0
Close	27
Days Gap	-1.85
Depreciation Amortization	456,245.7
Dollar Volume	1,305,496
Earnings Date	2026-05-11
EBIT	GBX -28.6M
EBITDA	GBX -28.2M
EPS	GBX -0.2
F Score	2
FCF	GBX -23M
FCF EV Yield	3,303.08x
Financing CF	242,961
Fiscal Year End	December
Founded	2,015
Investing CF	-14,860
Is Primary Listing	1
Last Report Date	2025-12-31
Ma150	39.4
Ma150ch	-32.73%
Ma20	31.5
Ma20ch	-15.87%
Net CF	-21,405,830
Next Earnings Date	2026-05-11
Open	26.5
Position In Range	250
Ppne	279,468.8
Price Date	2020-12-17
Ptbv Ratio	0.97
Relative Volume	0.37x
Revenue	371,500x
SBC By Revenue	1,519.6x
Share Based Comp	5,645,314
Tr6m	-34.57%
Volume	49,264
Z Score	25.39

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AIM/MPH pay a dividend?

Capital-return profile for this ticker.

Performance

AIM/MPH stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AIM/MPH?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AIM/MPH momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

17.9

Below 30: short-term oversold

Price vs 200-day MA

-23.8%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.60

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AIM/MPH

Hub-level FAQ points readers to the deeper analysis pages.

What is the current aim/MPH stock rating?

aim/MPH is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full aim/MPH analysis?

The full report lives at /stocks/aim/MPH/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for aim/MPH?

The latest report frames aim/MPH around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the aim/MPH page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.